Executive Director, Plasma Operations Jobs in Boca Raton, FL at CSL Limited
Title: Executive Director, Plasma Operations
Company: CSL Limited
Location: Boca Raton, FL
Salary: $250K — $500K+*
Category: Pharmaceuticals & Biotech
With operations in 35+ nations and ~ 22,000 employees worldwide, CSL is driven to develop and deliver a broad range of lifesaving therapies to treat disorders such as hemophilia and primary immune deficiencies, and vaccines to prevent influenza. Our therapies are also used in cardiac surgery, organ transplantation and burn treatment.
CSL is the parent company of CSL Behring and Seqirus. CSL Behring is a global leader in the protein biotherapeutics industry, focused on bringing to market biotherapies used to treat serious and often rare conditions. CSL Behring operates CSL Plasma , one of the world’s largest collectors of human plasma, which is used to create CSL’s therapies. Seqirus is the second largest influenza vaccine company in the world and is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally.
We invite you to take a look at the many career possibilities available around the globe and consider building your promising future at CSL by becoming a member of our team!
Responsible for developing and implementing the strategies, tactics, and polices for all US Center Operations for CSL Plasma (CPI). Total responsibility and accountability for ensuring that all production goals, financial performance, cost optimization, expense controls, quality, regulatory and customer requirements are met. Management and development of employee performance and retention. Effective annual and long-range planning, goal setting, competitive and market analysis, team coaching and training, and monitoring and adjusting plans accordingly to exceed performance expectations.
Establishes strategies and policies to ensure that overall center performance objectives are met including employee development, quality standards, financial and production performance. Develops and implements effective management tools to manage and monitor Center performance to ensure goals are exceeded. Establishes center production targets working with leadership and monitors center progress to ensure that production is exceeded. Implement strategies to achieve desired results that support the business plan to meet customer expectations.
Develops and implements strategies for fleet volume capacity and recommend that capacity is obtained through increase/decrease number of centers, center relocation and renovation projects. Directs the priorities of the engineering department on all site locations regarding size, location, lease options, etc.
Ensures that organizational design is aligned with business strategies. Develops and manages staffing strategies to ensure that effective programs are in place. Develops succession plans and oversee training, and career development of immediate staff.
Develops and implements continuous process improvements throughout Plasma Operations. Leads CPI organization to support programs that foster continuous improvement programs designed toward reducing cost and improving quality operations.
Responsible for center quality operations. Develops and implements programs in collaboration with the Regulatory Affairs (RA) and Quality Assurance (QA) groups to evaluate compliance to assure optimum product quality and employee and environmental safety. Responsible for the establishment and implementation, in conjunction with RA/QA, an effective SOP system to support compliance and auditing…
About CSL Limited
CSL Limited is a global specialty biotechnology company that researches, develops, manufactures and markets products to treat and prevent serious human medical conditions. CSLs product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. Founded in 1916 the Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. Under the first director, William Penfold, CSL commenced operation in the vacant Walter and Eliza Hall Institute building at the Melbourne Hospital in 1918, before moving to its purpose-built Parkville premises in the following year. After ongoing disputes with the Commonwealth Department of Health and its director, (John) Howard Cumpston, Penfold resigned in 1927 and was replaced by Frederic Morgan. Soon after Morgans appointment, CSL was drawn into a serious public health disaster when a batch of its diphtheria toxin-antitoxin was implicated in the deaths of 12 children in what became known as the 'Bundaberg tragedy' of 1928. Although CSLs manufacturing processes were absolved, its labelling procedures were seen to be in error, leading to an enduring focus on the highest standards across the facilitys production. In 1928 CSL also became involved in antivenene (antivenom) manufacture in conjunction with the snake venom research undertaken by Charles Kellaway at the Hall Institute. This led to the successful clinical testing of antivenene against tiger snake Notechis scutatus bite in 1930, and its commercial release in 1931. In 1934 the research on snake venoms was transferred from the Hall Institute to CSL under the direction of former snake showman, Tom 'Pambo' Eades. This represented the initiation of research at the laboratories – an outcome its directors had been seeking for over a decade. The relationship with the Hall Institute continued until World War II, particularly via joint projects on viral diseases including polio and influenza coordinated by Frank Macfarlane Burnet and Esmond 'Bill' Keogh. Keogh played an important role in the establishment of penicillin production at CSL in 1944 – a critical wartime achievement. The operation commenced plasma fractionation in 1952. Thereafter the range of antivenoms increased, including those against other snake species such as death adder (Acanthophis antarcticus) and the taipan (Oxyuranus scutellatus), plus spiders including the redback (Latrodectus hasselti) and – after much difficulty – the Sydney funnel-web (Atrax robustus). Much of this work, including the introduction in 1962 of a polyvalent antivenom against all of the major terrestrial Australian snakes, occurred under the direction of Saul Wiener, while from 1966 until the mid-1990s, venom research was coordinated by the eccentric but dedicated Struan Sutherland.